BMS and Dr Reddy’s settle Revlimid suit with generics licence

Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

BMS and Dr Reddy’s settle Revlimid suit with generics licence

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features